Details of the Drug Combination

General Information of Drug Combination (ID: DCUOXAK)

Drug Combination Name
Terameprocol FORMESTANE
Indication
Disease Entry Status REF
Malignant melanoma Investigative [1]
Component Drugs Terameprocol   DMC3P45 FORMESTANE   DMWIDJK
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: UACC62
Zero Interaction Potency (ZIP) Score: 0.57
Bliss Independence Score: 1.85
Loewe Additivity Score: 1.55
LHighest Single Agent (HSA) Score: 0.69

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Terameprocol
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 2 [2]
Terameprocol Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Transcription factor Sp1 (SP1) TTZEP6S SP1_HUMAN Modulator [2]
------------------------------------------------------------------------------------
Indication(s) of FORMESTANE
Disease Entry ICD 11 Status REF
Breast cancer 2C60-2C65 Withdrawn from market [3]
FORMESTANE Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Aromatase (CYP19A1) TTSZLWK CP19A_HUMAN Inhibitor [4]
------------------------------------------------------------------------------------
FORMESTANE Interacts with 2 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Adenylate kinase isoenzyme 1 (AK1) OT614AR3 KAD1_HUMAN Increases ADR [5]
17-beta-hydroxysteroid dehydrogenase type 1 (HSD17B1) OT6EBDHM DHB1_HUMAN Decreases Activity [6]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Adult acute myeloid leukemia DCI7XJI HL-60(TB) Investigative [7]
Astrocytoma DCDK4FE U251 Investigative [7]
Childhood T acute lymphoblastic leukemia DCQ06SU CCRF-CEM Investigative [7]
Clear cell renal cell carcinoma DCMXN65 786-0 Investigative [7]
Clear cell renal cell carcinoma DC4CMM2 CAKI-1 Investigative [7]
Glioma DCBT0OR SF-295 Investigative [7]
Plasma cell myeloma DCI323K RPMI-8226 Investigative [7]
Colon adenocarcinoma DCZW91A COLO 205 Investigative [8]
Adenocarcinoma DCQ5KCF OVCAR3 Investigative [1]
Adenocarcinoma DCTGLTL HCT116 Investigative [1]
Adenocarcinoma DCQEH2M SW-620 Investigative [1]
Adenocarcinoma DC23I9R HT29 Investigative [1]
Amelanotic melanoma DCU7YSO M14 Investigative [1]
Cutaneous melanoma DCQ01SW SK-MEL-28 Investigative [1]
High grade ovarian serous adenocarcinoma DCOY3T3 NCI\\/ADR-RES Investigative [1]
Large cell lung carcinoma DCCH7JN NCI-H460 Investigative [1]
Minimally invasive lung adenocarcinoma DCP5MTL NCI-H322M Investigative [1]
Prostate carcinoma DCCJYXM PC-3 Investigative [1]
------------------------------------------------------------------------------------
⏷ Show the Full List of 18 DrugCom(s)

References

1 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125976
2 Terameprocol, a novel site-specific transcription inhibitor with anticancer activity. IDrugs. 2008 Mar;11(3):204-14.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4 The taiwaniaquinoids: a review. J Nat Prod. 2010 Feb 26;73(2):284-98.
5 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
6 Mammalian lignans and genistein decrease the activities of aromatase and 17beta-hydroxysteroid dehydrogenase in MCF-7 cells. J Steroid Biochem Mol Biol. 2005 Apr;94(5):461-7.
7 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125966
8 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1126165